Thromboxane receptors antagonists and/or synthase inhibitors.

@article{Dav2012ThromboxaneRA,
  title={Thromboxane receptors antagonists and/or synthase inhibitors.},
  author={Giovanni Davı̀ and Francesca Santilli and Natale Vazzana},
  journal={Handbook of experimental pharmacology},
  year={2012},
  volume={210},
  pages={
          261-86
        }
}
Atherothrombosis is the major cause of mortality and morbidity in Western countries. Several clinical conditions are characterized by increased incidence of cardiovascular events and enhanced thromboxane (TX)-dependent platelet activation. Enhanced TX generation may be explained by mechanisms relatively insensitive to aspirin. More potent drugs possibly overcoming aspirin efficacy may be desirable. Thromboxane synthase inhibitors (TXSI) and thromboxane receptor antagonists (TXRA) have the… 
Antiplatelet Therapy: Targeting the TxA2 Pathway
TLDR
The TxA2 pathway is a major target in the treatment of cardiovascular disease and drugs, with either inhibitory effects on Tx synthase or antagonist effects on TP, have been developed with the hope of providing a better, more complete inhibition.
Interactions between thromboxane A₂, thromboxane/prostaglandin (TP) receptors, and endothelium-derived hyperpolarization.
TLDR
The mechanisms through which thromboxane A2 interacts with and modulates EDH are discussed, and the implications of such cross-talk in vasodilator control in health and disease are considered.
A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models.
TLDR
This study suggests nstpbp5185, an orally selective anti-thrombotic agent, acting through blockade of TXA2 receptor, may be efficacious for prevention or treatment of pathologic thrombosis.
NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension
TLDR
NTP42 and antagonism of the TP signalling pathway have a relevant role in alleviating the pathophysiology of PAH, representing a novel therapeutic target with marked benefits over existing standard-of-care therapies.
Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation
TLDR
The understanding of TP receptor function increased the current knowledge of the pathogenesis of atherosclerosis and thrombosis, highlighting the great impact that this receptor has in cardiovascular disorders.
The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review
TLDR
There is insufficient evidence to suggest that thromboxane could be used in clinical practice as a marker of ischemic stroke, and it was shown that a high concentration of TXB2 may be a risk factor for isChemic stroke or ischeMIC heart disease.
Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane‐mediated thromboxane A2 receptor activation
TLDR
Experimental and clinical data suggest that selected isoprostanes may represent important alternative activators of the TP receptor when endogenous TxA2 levels are low, for example, in aspirin‐treated individuals with CVD.
Antagonism of the Thromboxane-Prostanoid Receptor is Cardioprotective against Right Ventricular Pressure Overload
TLDR
It is suggested that TP receptor antagonism may improve RV adaptation in situations of pressure overload by decreasing fibrosis and TGF-β signaling.
Investigation of a Thromboxane A2 Receptor–Based Vaccine for Managing Thrombogenesis
TLDR
Light is shed on TPR's structural biological features, and it is demonstrated that the C‐terminus of the second extracellular loop domain may define a new therapeutic target and a TPR vaccine‐based approach that should have therapeutic applications.
...
...

References

SHOWING 1-10 OF 83 REFERENCES
New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
TLDR
This review will propose a description of the recently described thromboxane modulators of major interest, which combine another pharmacological activity such as, platelet activating factor antagonism, angiotensin II antagonism or 5-lipoxygenase inhibition.
Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?
TLDR
More recent findings support the critical role of TP-receptor in other pathophysiological aspects of atherothrombosis and the possibility of combining anti-platelet activity with an anti-atherosclerotic effect via selective TP- receptor inhibitors could have important implications especially in clinical conditions associated with increased production of prostanoids.
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2
TLDR
It is shown that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI2receptor but are depressed in mice genetically deficiencies in the TxA2 receptor (TP) or treated with a TP antagonist.
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
TLDR
Comparisons of the effects of aspirin and the TP receptor antagonist S18886 suggest that blockade of TP receptors inhibits atherosclerosis by a mechanism independent of platelet-derived TxA(2), perhaps by preventing the expression of adhesion molecules whose expression is stimulated by eicosanoids other than Tx a(2).
TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus
TLDR
Targeting TP receptor, a common downstream pathway for both platelet and extraplatelet TXA2 as well as for isoprostanes, may be an useful antithrombotic intervention in clinical settings, such as diabetes mellitus characterized by persistently enhanced thromboxane-dependent platelet activation.
Biosynthesis and pharmacological modulation of thromboxane in humans.
Thromboxane (TXA2), a potent proaggregatory and vasoconstricting eicosanoid, is produced at a very low rate and is cleared rapidly from the human circulation. Its chemically stable hydration product,
TP Receptor Antagonism: A New Concept in Atherothrombosis and Stroke Prevention
TLDR
Terutroban (Triplion® or S18886), a new oral specific TP receptor antagonist, has, aside from being an antithrombotic agent, important vascular properties, It improves endothelial function and has an antiatherosclerotic effect.
The biochemical pharmacology of thromboxane synthase inhibition in man.
TLDR
Investigations of their efficacy in human disease have proven disappointing, and compounds of longer duration of action are required to test the hypothesis that thromboxane synthase inhibitors are efficacious inhuman disease.
Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism
TLDR
TP antagonism is more effective than combined inhibition of COX-1 and COx-2 in retarding atherogenesis in Apobec-1/LDLR DKO mice, which perhaps reflects activation of the receptor by multiple ligands during disease initiation and early progression.
...
...